John Magenau, MD
Hematology · Ann Arbor, MINPI 1285833954
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,844 of the $12,908 with a category attached, or 99.5%. CSL Behring accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest.
Across 17 payments — averaging $759.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$13K
- Gilead$40
Across 88 payments — averaging $24,637 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$966K
- Merck$932K
- National Marrow Donor Program$252K
- Syndax Pharmaceuticals, Inc.$13K
- Novartis$5K
What the payments were for
- Speaking & faculty fees$12,844100%
- Food & beverage$240%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 15 | $12,868 |
| Gilead | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zemaira$5,917
How this compares
$12,908 in reported general payments places this provider in the 75th percentile of 50 hematology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 12 | $171,121 |
| Budesonide DrBudesonide | 13 | $893 |
| Hydrocortisone | 26 | $691 |
| Fluconazole | 18 | $417 |
| Acyclovir | 30 | $377 |
| Prednisone | 28 | $211 |
| Omeprazole | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Other hematology in Ann Arbor
- Matthew PiankoAnn Arbor$51K
- Sami MalekAnn Arbor$49K
- Yasmin KarimiAnn Arbor$47K
- Kristen PettitAnn Arbor$45K
- Samuel SilverAnn Arbor$23K
- Jordan SchaeferAnn Arbor$14K
- Sarah AnandAnn Arbor$14K
- Charles FoucarAnn Arbor$11K
- Patrick BurkeAnn Arbor$6K
- Dale BixbyAnn Arbor$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.